More precisely, mRNA and protein levels of BCL-2 and XIAP were reduced in the presence of SAFit, suggesting that, by counteracting NF-κB activation, SAFit is able to turn off the survival pathways of the tumor. This evidence concerns the gene BCL2 and neoplasm.